Download PDF
Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie 2016; 03(02): 147-158
DOI: 10.1055/s-0042-106195
Fortbildung
Periphere Arterien
© Georg Thieme Verlag KG Stuttgart · New York

Zelltransplantation bei chronischer Extremitätenischämie

Berthold Amann
,
Holger Lawall
,
Claas Lüdemann
Further Information

Publication History

Publication Date:
01 July 2016 (online)

Also available at
    Permissions and Reprints
Fazit

Die autologe Stammzelltherapie ist nach den bislang vorliegenden Studien ein möglicher neuer Ansatz in der Behandlung der pAVK. Erste Erfahrungen zeigen eine gute Praktikabilität und sehr gute Sicherheit der Therapie. Die vorliegenden Ergebnisse der überwiegend unkontrollierten Studien zeugen von einer Verbesserung der Durchblutung, einhergehend mit klinischer Verbesserung. Eine erfolgreiche Umsetzung in die Praxis hängt von den Ergebnissen größerer kontrollierter Untersuchungen ab, die zurzeit laufen.

Mit der Stimulation der Gefäßneubildung durch autologe Stammzellentransplantation ergeben sich in der Zukunft eventuell neue oder ergänzende Alternativen zu den bisherigen Konzepten der Behandlung der pAVK. Dies gilt vor allem für Patienten, bei denen eine progrediente Verschlechterung der Ischämie mit pharmakologischen Maßnahmen nicht verhindert werden kann und bei denen eine gefäßchirurgische oder interventionelle Revaskularisation nicht möglich ist. Die Erfahrungen der Autoren sind ermutigend; bei sorgfältiger Selektion der Patienten (erhaltungswürdige Extremität, noch messbare Restdurchblutung mit einem Knöchel-Arm-Index von mehr als 0,1 und einem transkutanen Sauerstoffpartialdruck von über 0 mmHg) ist die technisch dank der Automatisierung und der bettseitigen Durchführbarkeit einfach gewordene autologe Zelltherapie eine gute Möglichkeit, um Majoramputationen zu verhindern.

 

  • Literatur

  • 1 Malyar N, Fürstenberg T, Wellmann J et al. Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysis. Eur Heart J 2013; 34: 2706-2714
    CrossrefGoogle Scholar
  • 2 Norgren L, Hiatt WR, Dormandy JA. TASC II Working Group et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl. 01) 1-S75
    CrossrefGoogle Scholar
  • 3 Adam DJ, Beard JD, Cleveland T et al. BASIL Trial participants. Bypass versus angioplasty in severe ischemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005; 366: 1925-1934
    CrossrefPubMedGoogle Scholar
  • 4 ClinicalTrials.gov. Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL). 2015 Im Internet: https://clinicaltrials.gov/ct2/show/results/NCT00596752 [Stand: 3.4.2016]
    Google Scholar
  • 5 Lepäntalo M. The path from art to evidence in treating critical limb ischemia – reflections on 35 years’ experience. Scan J Surg 2012; 101: 78-85
    Google Scholar
  • 6 Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease – a systematic review and meta-analysis of randomized, controlled trials. Vasa 2013; 42: 331-339
    CrossrefGoogle Scholar
  • 7 Miao YL, Wu W, Li BW et al. Clinical effectiveness of gene therapy on critical limb ischemia: a meta-analysis of 5 randomized controlled clinical trials. Vasc Endovascular Surg 2014; 48: 372-377
    Google Scholar
  • 8 Asahara T, Murahara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967
    CrossrefPubMedGoogle Scholar
  • 9 Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularisation. J Clin Invest 1999; 103: 1231-1236
    CrossrefGoogle Scholar
  • 10 Higashi Y, Kimura M, Hara K et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilatation in patients with limb ischemia. Circulation 2004; 109: 1215-1218
    CrossrefGoogle Scholar
  • 11 Shintani S, Murohara T, Ikeda H et al. Augmentation of postnatal neovascularisation with autologous bone marrow transplantation. Circulation 2001; 103: 897-903
    CrossrefGoogle Scholar
  • 12 Ziegelhoeffer T, Fernandez B, Kostin S et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 2004; 94: 230-238
    CrossrefGoogle Scholar
  • 13 Ding H, Triggle CR. Endothelial dysfunction in diabetes: multiple targets for treatment. Pflugers Arch 2010; 459: 977-994
    CrossrefGoogle Scholar
  • 14 Hamed S, Brenner B, Abassi Z. Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. Thromb Res 2010; 126: 166-174
    CrossrefGoogle Scholar
  • 15 Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009; 20: 295-302
    CrossrefGoogle Scholar
  • 16 Vink H, Constantinescu AA, Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion. Circulation 2000; 101: 1500-1502
    CrossrefGoogle Scholar
  • 17 Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427-435
    CrossrefGoogle Scholar
  • 18 Esato K, Hamano K, Li TS et al. Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease. Cell Transplant 2002; 11: 747-752
    Google Scholar
  • 19 Saigawa T, Kato K, Ozawa T et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J 2004; 68: 1189-1193
    CrossrefGoogle Scholar
  • 20 Nizankowski R, Petriczek T, Skotnicki A et al. The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation. Kardiol Pol 2005; 63: 351-360 ; discussion 361
    Google Scholar
  • 21 Durdu S, Akar AR, Arat M et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II–III thromboangiitis obliterans. J Vasc Surg 2006; 44: 732-739
    CrossrefGoogle Scholar
  • 22 Kajiguchi M, Kondo T, Izawa H et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 2007; 71: 196-201
    CrossrefGoogle Scholar
  • 23 Huang PP, Yang XF, Li SZ et al. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007; 98: 1335-1342
    Google Scholar
  • 24 Bartsch T, Brehm M, Zeus T et al. Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study). Clin Res Cardiol 2007; 96: 891-899
    CrossrefGoogle Scholar
  • 25 Hernández P, Cortina L, Artaza H et al. Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis 2007; 194: e52-e56
    CrossrefGoogle Scholar
  • 26 Van Tongeren RB, Hamming JF, Fibbe WE et al. Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino) 2008; 49: 51-58
    Google Scholar
  • 27 De Vriese AS, Billiet J, Van Droogenbroeck J et al. Autologous transplantation of bone marrow mononuclear cells for limb ischemia in a caucasian population with atherosclerosis obliterans. J Intern Med 2008; 263: 395-403
    CrossrefGoogle Scholar
  • 28 Gu YQ, Zhang J, Guo LR et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chin Med J (Engl) 2008; 121: 963-967
    Google Scholar
  • 29 Napoli C, Farzati B, Sica V et al. Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia. Eur J Cardiovasc Prev Rehabil 2008; 15: 709-718
    CrossrefGoogle Scholar
  • 30 Amann B, Luedemann C, Ratei R et al. Autologous bone marrow transplantaion increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transpl 2009; 18: 371-380
    CrossrefGoogle Scholar
  • 31 Procházka V, Gumulec J, Jalůvka F et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplantation 2010; 19: 1413-1424
    CrossrefGoogle Scholar
  • 32 Walter DH, Krankenberg H, Balzer JO et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4: 26-37
    CrossrefGoogle Scholar
  • 33 Ozturk A, Kucukardali Y, Tangi F et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. J Diabetes Complications 2012; 26: 29-33
    CrossrefGoogle Scholar
  • 34 Benoit E, O’Donnell TF, Patel AN. Safety and efficacy of autologous cell therapy in critical lim ischemia: a systematic review. Cell Transplantation 2013; 22: 545-562
    CrossrefGoogle Scholar
  • 35 Liu FP, Dong JJ, Sun SJ et al. Autologous bone marrow stem cell transplantation in critical limb ischemia: a meta-analysis of randomized controlled trials. Chin Med J (Engl) 2012; 125: 4296-4300
    Google Scholar
  • 36 Teraa M, Sprengers RW, van der Graaf Y. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013; 258: 922-929
    CrossrefGoogle Scholar
  • 37 Lee KB, Kang ES, Kim AK et al. Stem cell therapy in patients with thromboangiitis obliterans: assessment of the long-term clinical outcome and analysis of the prognostic factors. Int J Stem Cells 2011; 4: 88-98
    CrossrefGoogle Scholar
  • 38 Matoba S, Tatsumi T, Murohara T et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008; 156: 1010-1018
    CrossrefGoogle Scholar
  • 39 Iafrati MD, Hallett JW, Geils G et al. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical lim ischemia. J Vasc Surg 2011; 54: 1650-1658
    CrossrefGoogle Scholar
  • 40 Benoit E, O’Donnell Jr TF, Iafrati MD et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 2011; 9: 165
    CrossrefGoogle Scholar
  • 41 Lu D, Chen B, Liang Z et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011; 92: 26-36
    CrossrefGoogle Scholar
  • 42 Powell RJ, Comerota AJ, Berceli SA et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg 2011; 54: 1032-1041
    CrossrefGoogle Scholar
  • 43 Arai M, Misao Y, Nagai H et al. Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J 2006; 70: 1093-1098
    CrossrefGoogle Scholar
  • 44 Huang P, Li S, Han M et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28: 2155-2160
    CrossrefGoogle Scholar
  • 45 Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 2011; 53: 445-453
    CrossrefGoogle Scholar